Provided by Tiger Trade Technology Pte. Ltd.

Benitec Biopharma

13.48
+0.47003.61%
Post-market: 13.480.00000.00%19:30 EDT
Volume:160.14K
Turnover:2.19M
Market Cap:461.76M
PE:-14.44
High:13.98
Open:13.14
Low:13.03
Close:13.01
52wk High:16.76
52wk Low:9.85
Shares:34.25M
Float Shares:17.93M
Volume Ratio:0.78
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9338
EPS(LYR):-1.0472
ROE:-29.58%
ROA:-19.93%
PB:2.52
PE(LYR):-12.87

Loading ...

Company Profile

Company Name:
Benitec Biopharma
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
19
Office Location:
3940 Trust Way,Hayward,California,United States
Zip Code:
94545
Fax:
- -
Introduction:
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.

Directors

Name
Position
Jerel A. Banks
Chairman of the Board and Chief Executive Officer
Edward Smith
Independent Director
J. Kevin Buchi
Independent Director
Peter Francis
Independent Director
David Friedman
Director
Kishen Mehta
Director
Sharon Mates
Director

Shareholders

Name
Position
Jerel A. Banks
Chairman of the Board and Chief Executive Officer
Sophie Mukadam
Chief Operating Officer
Megan Boston
Chief Financial Officer and Secretary